As Ozempic/Wegovy frenzy continues, Morgan Stanley lifts forecasts for weight-loss drugs to $77 billion

Brasil Notícia Notícia

As Ozempic/Wegovy frenzy continues, Morgan Stanley lifts forecasts for weight-loss drugs to $77 billion
Brasil Últimas Notícias,Brasil Manchetes
  • 📰 MarketWatch
  • ⏱ Reading Time:
  • 35 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 17%
  • Publisher: 97%

Morgan Stanley on Friday lifted its forecast for weight-loss drugs to $77 billion, as patient demand for the medicines has outstripped supply and been fueled...

Morgan Stanley on Friday lifted its forecast for annual sales of weight-loss drugs to $77 billion, as patient demand for the medicines has outstripped supply and been fueled by a social-media frenzy.Already, the analysts say Novo Nordisk’s Wegovy could... Morgan Stanley on Friday lifted its forecast for annual sales of weight-loss drugs to $77 billion, as patient demand for the medicines has outstripped supply and been fueled by a social-media frenzy.

“The greater focus on weight management has spilled over into an increasingly weight-centric approach to treating diabetes. We anticipate that over the next 24 months, this weight-centric focus will broaden into new health complications, including heart failure, sleep apnea and kidney disease, which will expand reimbursement into the U.S. Medicare population,” says the note, which counts 16 analysts as contributors.Novo Nordisk NVO NOVO.

Biopharmas are hoping to capture a slice of the pie, with firms having drugs in the pipeline including Zealand Pharma ZEAL , Structure Therapeutics GPCR , Sciwind Biosciences , Regor Therapeutics and Altimmune ALT , the report says.

Resumimos esta notícia para que você possa lê-la rapidamente. Se você se interessou pela notícia, pode ler o texto completo aqui. Consulte Mais informação:

MarketWatch /  🏆 3. in US

Brasil Últimas Notícias, Brasil Manchetes

Similar News:Você também pode ler notícias semelhantes a esta que coletamos de outras fontes de notícias.

Morgan Stanley upgrades Anheuser-Busch InBev, says it's attractive valued after Bud Light controversyMorgan Stanley upgrades Anheuser-Busch InBev, says it's attractive valued after Bud Light controversyA decline in commodity prices should boost the parent company behind Bud Light. The U.S.-listed shares of the beverage company is down about 2.7% this year.
Consulte Mais informação »

Morgan Stanley's top clean power picks including 2 stocks with 80% upsideMorgan Stanley's top clean power picks including 2 stocks with 80% upsideThe firm has stocks to watch as green energy becomes more popular.
Consulte Mais informação »

Victims want Morgan Stanley to answer for ex-financial advisor's Ponzi schemeVictims want Morgan Stanley to answer for ex-financial advisor's Ponzi schemeVictims filed arbitration claims against Morgan Stanley, alleging that it failed to reasonably supervise its employee.
Consulte Mais informação »

Swedish landlord SBB raising $228 mln capital from Morgan Stanley fundSwedish landlord SBB raising $228 mln capital from Morgan Stanley fundSwedish property group SBB said on Friday its unit will issue preference shares worth 2.36 billion Swedish crowns ($228 million) to an investment fund managed by Morgan Stanley , in a bid to boost its liquidity and financial profile.
Consulte Mais informação »

Goldman Sachs’ profit plunges 58% in second quarterGoldman Sachs’ profit plunges 58% in second quarterGoldman’s second quarter results lag behind those of rivals JPMorgan Chase, Bank of America, Morgan Stanley, and Citigroup.
Consulte Mais informação »

Bud Light sales are still falling, but investors get it at this point. Here's what Morgan Stanley says they might be missing.Bud Light sales are still falling, but investors get it at this point. Here's what Morgan Stanley says they might be missing.Morgan Stanley analysts said the impact of the Bud Light boycott was already reflected in the share price of the beer's parent company, Anheuser-Busch InBev.
Consulte Mais informação »



Render Time: 2025-02-26 21:22:15